| Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play? H Hazendonk, I van Moort, RAA Mathôt, K Fijnvandraat, FWG Leebeek, ... Blood reviews 32 (4), 265-271, 2018 | 56 | 2018 |
| Facilitating the implementation of pharmacokinetic‐guided dosing of prophylaxis in haemophilia care by discrete choice experiment J Lock, EW de Bekker‐Grob, G Urhan, M Peters, K Meijer, P Brons, ... Haemophilia 22 (1), e1-e10, 2016 | 31 | 2016 |
| Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment H Hazendonk, JM Heijdra, NCB de Jager, HC Veerman, J Boender, ... Haemophilia 24 (3), 460-470, 2018 | 29 | 2018 |
| The “OPTI-CLOT” trial HCAM Hazendonk, I van Moort, K Fijnvandraat, MJHA Kruip, ... Thrombosis and haemostasis 114 (09), 639-644, 2015 | 28 | 2015 |
| Cross-evaluation of pharmacokinetic-guided dosing tools for factor VIII T Preijers, I van Moort, K Fijnvandraat, FWG Leebeek, MH Cnossen, ... Thrombosis and haemostasis 118 (03), 514-525, 2018 | 25 | 2018 |
| Analytical variation in factor VIII one‐stage and chromogenic assays: experiences from the ECAT external quality assessment programme I van Moort, P Meijer, D Priem‐Visser, AJ van Gammeren, ... Haemophilia 25 (1), 162-169, 2019 | 17 | 2019 |
| Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling A Janssen, M Hoogendoorn, MH Cnossen, RAA Mathôt, ... CPT: Pharmacometrics & Systems Pharmacology 11 (8), 1100-1110, 2022 | 15 | 2022 |
| Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery T Preijers, H Hazendonk, R Liesner, P Chowdary, MHE Driessens, D Hart, ... Journal of Thrombosis and Haemostasis 16 (11), 2196-2207, 2018 | 14 | 2018 |
| OPTI-CLOT” and “WIN” study group. Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: identifying the need for personalized treatment H Hazendonk, JM Heijdra, NCB de Jager, HC Veerman, J Boender, ... Haemophilia 24 (3), 460-470, 2018 | 13 | 2018 |
| Deep compartment models: a deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling A Janssen, FWG Leebeek, MH Cnossen, RAA Mathôt, ... CPT: Pharmacometrics & Systems Pharmacology 11 (7), 934-945, 2022 | 11 | 2022 |
| Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial I van Moort, T Preijers, LH Bukkems, HCAM Hazendonk, JG van der Bom, ... The Lancet Haematology 8 (7), e492-e502, 2021 | 11 | 2021 |
| A novel, enriched population pharmacokinetic model for recombinant factor VIII-Fc fusion protein concentrate in hemophilia A patients LH Bukkems, JM Heijdra, M Mathias, PW Collins, CRM Hay, RC Tait, ... Thrombosis and haemostasis 120 (05), 747-757, 2020 | 10 | 2020 |
| SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders MH Cnossen, I van Moort, SH Reitsma, MPM de Maat, REG Schutgens, ... Journal of Thrombosis and Haemostasis 20 (9), 2001-2011, 2022 | 9 | 2022 |
| Design and Usability of an Electronic Health Record—Integrated, Point-of-Care, Clinical Decision Support Tool for Modeling and Simulation of Antihemophilic Factors SM Abdel-Rahman, H Gill, SL Carpenter, P Gueye, B Wicklund, ... Applied Clinical Informatics 11 (02), 253-264, 2020 | 9 | 2020 |
| One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients NCB de Jager, LH Bukkems, JM Heijdra, CH Hazendonk, K Fijnvandraat, ... Journal of Thrombosis and Haemostasis 18 (2), 295-305, 2020 | 8 | 2020 |
| Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients I van Moort, T Preijers, HCAM Hazendonk, REG Schutgens, ... British journal of clinical pharmacology 87 (6), 2602-2613, 2021 | 6 | 2021 |
| Von willebrand factor and factor VIII clearance in perioperative hemophilia A patients I van Moort, LH Bukkems, JM Heijdra, REG Schutgens, ... Thrombosis and haemostasis 120 (07), 1056-1065, 2020 | 6 | 2020 |
| Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation RMW de Laat-Kremers, M Ninivaggi, I van Moort, M de Maat, B de Laat Scientific Reports 11 (1), 15572, 2021 | 5 | 2021 |
| Mutations in Neurobeachin-like 2 do not impact Weibel-Palade body biogenesis and von Willebrand factor secretion in gray platelet syndrome Endothelial Colony Forming Cells M Kat, I van Moort, PE Bürgisser, TW Kuijpers, M Hofman, M Favier, ... Research and practice in thrombosis and haemostasis 7 (2), 100086, 2023 | 2 | 2023 |
| Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patients M Swinkels, F Atiq, PE Bürgisser, I van Moort, K Meijer, J Eikenboom, ... British journal of haematology 197 (4), 497-501, 2022 | 2 | 2022 |
